New US military guidelines require annual testosterone screening for male service members aged 30 and above, as Defence Secretary Pete Hegseth links hormonal health to combat readiness.

The US Pentagon has introduced new clinical guidelines requiring male active-duty and reserve service members aged 30 and above to undergo annual testosterone screening, according to Reuters. The policy takes immediate effect and is part of Defence Secretary Pete Hegseth’s broader push to address hormonal and metabolic health among military personnel.

Under the new rules, testosterone testing will become part of routine health assessments for men over 30. Male service members below the age threshold will generally not be screened unless they request a test or show symptoms associated with testosterone deficiency.

The Pentagon says the initiative is aimed at identifying treatable health problems that could affect the physical performance and long-term readiness of US troops.

Annual Tests For Men

The new guidelines establish routine annual blood testing for testosterone deficiency among male service members aged 30 and older.

Doctors can order tests for younger personnel when symptoms suggest a possible hormonal problem. This approach means that routine screening will focus primarily on the older segment of the military population while allowing younger troops access to testing when medically indicated.

The Pentagon's move represents a significant expansion of testosterone screening within the US armed forces.

Different Rules For Women

The guidelines do not require female service members to undergo routine testosterone blood tests.

Instead, military doctors have been instructed to pay attention to symptoms that could indicate hormonal or metabolic problems. These include persistent fatigue and disrupted menstrual cycles, which can also be associated with inadequate energy availability.

The guidance additionally addresses testosterone treatment for some postmenopausal women. Doctors may prescribe testosterone on an off-label basis in specific circumstances, particularly when a woman has unusually low sexual desire.

Hegseth Pushes Readiness

Defence Secretary Pete Hegseth announced plans for broader testosterone screening in July as part of his focus on the physical condition of US service members.

The Pentagon has linked the initiative to concerns about hormonal health, energy levels and metabolic issues that could affect personnel working in physically demanding environments.

For the Trump administration, military readiness has become a central theme in discussions about the health and physical standards of American troops.

The new guidelines are intended to provide military medical personnel with a consistent framework for identifying and managing testosterone-related conditions.

Medical Experts Raise Concerns

The decision has nevertheless prompted questions from medical professionals about the value of routine testosterone screening among otherwise healthy people.

Experts have cautioned that testosterone levels can vary and that a low reading alone does not necessarily establish a medical condition requiring treatment. Symptoms, medical history and repeat testing may also need to be considered.

Doctors have warned that unnecessarily treating people with testosterone could expose them to avoidable risks.

One concern is that broad screening could lead to more diagnoses and prescriptions without sufficient evidence that treatment would improve health or military performance in otherwise healthy service members.

Testosterone Treatment Risks

Testosterone therapy is not risk-free and can have consequences that need to be considered before treatment.

Medical concerns associated with inappropriate testosterone use include effects on fertility and other potential side effects. This has led experts to stress the importance of distinguishing genuine testosterone deficiency from temporary or clinically insignificant changes in hormone levels.

The Pentagon guidelines are therefore expected to play an important role in determining which service members receive further evaluation or treatment after testing.

FDA Meeting In September

The debate comes as the US Food and Drug Administration prepares to hold an expert meeting in September to examine testosterone's medical use and related issues.

The FDA review could add to the wider discussion over when testosterone testing is appropriate and which patients are likely to benefit from treatment.

The timing is particularly significant because the Pentagon is expanding testosterone screening across a large military population while medical experts continue to debate the benefits and limitations of broad testing.

Readiness Versus Evidence

The Pentagon's policy places hormonal health directly within the military's broader readiness strategy. Officials argue that identifying health problems early could help service members remain physically capable and operationally effective.

Critics, however, say military readiness objectives should not replace evidence-based medical decision-making.

As the new screening programme takes effect, its impact will depend not only on how many troops are found to have low testosterone but also on whether diagnosis and treatment lead to measurable improvements in health, performance and readiness.

The upcoming FDA meeting could provide further clarity as the US military begins implementing one of its most extensive hormone-screening initiatives.